Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia

Nemonoxacin, a novel nonfluorinated quinolone, exhibits potent in vitro and in vivo activities against community-acquired pneumonia (CAP) pathogens, including multidrug-resistant Streptococcus pneumoniae. Patients with mild to moderate CAP (n = 265) were randomized to receive oral nemonoxacin (750 m...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: van Rensburg, Dirkie J. J., Perng, Reury-Perng, Mitha, Ismail H., Bester, Andrè J., Kasumba, Joseph, Wu, Ren-Guang, Ho, Ming-Lin, Chang, Li-Wen, Chung, David T., Chang, Yu-Ting, King, Chi-Hsin R., Hsu, Ming-Chu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology (ASM) 2010
Pynciau:
Clinical Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2944601/
https://ncbi.nlm.nih.gov/pubmed/20660689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00295-10
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg